Vaxcyte (PCVX) News Today $85.96 -1.12 (-1.29%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Segall Bryant & Hamill LLCSegall Bryant & Hamill LLC trimmed its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 3.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,056 shares of the company's stock after selling 6,376 shares during the period. SegaNovember 21 at 5:13 AM | marketbeat.comPrincipal Financial Group Inc. Purchases 34,287 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Principal Financial Group Inc. raised its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 186.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,702 shares of the company's stock after purchasing an additionalNovember 21 at 3:03 AM | marketbeat.comKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmNovember 21 at 12:19 AM | markets.businessinsider.comJennison Associates LLC Decreases Stake in Vaxcyte, Inc. (NASDAQ:PCVX)Jennison Associates LLC lowered its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,237,430 shares of the company's stock after selling 145,701 sharesNovember 20 at 7:17 AM | marketbeat.comBuy Rating on Vaxcyte Reaffirmed Amid Market Overreaction to Vaccine Policy ConcernsNovember 19 at 6:21 AM | markets.businessinsider.comVaxcyte, Inc. (NASDAQ:PCVX) is First Turn Management LLC's 5th Largest PositionFirst Turn Management LLC trimmed its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 18.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,985 shares of the company'November 19 at 6:16 AM | marketbeat.comVictory Capital Management Inc. Has $29.14 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)Victory Capital Management Inc. trimmed its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 255,040 shares of the compaNovember 18 at 4:03 AM | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Average Recommendation of "Buy" by AnalystsVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has earned a consensus rating of "Buy" from the seven analysts that are presently covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that haveNovember 17, 2024 | marketbeat.comCuri RMB Capital LLC Purchases New Position in Vaxcyte, Inc. (NASDAQ:PCVX)Curi RMB Capital LLC purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 7,901 shares of the company's stock, valued at approximately $903,000. A numbeNovember 16, 2024 | marketbeat.comLos Angeles Capital Management LLC Takes $1.02 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)Los Angeles Capital Management LLC bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 8,895 shares of the company's stock, valued at approximately $1,016,000. Other hedge funds and other institutiNovember 16, 2024 | marketbeat.comVaccine makers fall after Trump nominates RFK to head HHSNovember 15, 2024 | markets.businessinsider.comVaxcyte Enters Oversold Territory (PCVX)November 15, 2024 | nasdaq.comVaxcyte (NASDAQ:PCVX) Sees Unusually-High Trading Volume - What's Next?Vaxcyte (NASDAQ:PCVX) Sees Strong Trading Volume - Here's WhyNovember 15, 2024 | marketbeat.comVaxcyte, Inc.: Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult ProgramsNovember 12, 2024 | finanznachrichten.deVaxcyte gets FDA Breakthrough Therapy Designation for its pneumococcal disease treatmentNovember 12, 2024 | msn.comVaxcyte provides regulatory updates on VAX-31 programsNovember 12, 2024 | markets.businessinsider.comVaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult ProgramsNovember 12, 2024 | globenewswire.comWCM Investment Management LLC Has $15.94 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)WCM Investment Management LLC increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 52.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,847 shares of the company's stock after aNovember 12, 2024 | marketbeat.comLisanti Capital Growth LLC Purchases 13,175 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Lisanti Capital Growth LLC lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 68.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 32,515 shares of the company's stock after acquiring an additional 13,175 shares during the pNovember 11, 2024 | marketbeat.comCantor Fitzgerald Increases Earnings Estimates for VaxcyteNovember 11, 2024 | americanbankingnews.comCantor Fitzgerald Forecasts Stronger Earnings for VaxcyteVaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Cantor Fitzgerald increased their FY2024 earnings per share estimates for Vaxcyte in a research report issued to clients and investors on Wednesday, November 6th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings of (November 11, 2024 | marketbeat.com269,121 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by TimesSquare Capital Management LLCTimesSquare Capital Management LLC purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 269,121 shares of the company's stock, valued at approximately $30,752,000.November 10, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 2,366 SharesNovember 9, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $245,803.74 in StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CEO Grant Pickering sold 2,366 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the sale, the chief executive officer now owns 137,398 shares in the company, valued at $14,274,278.22. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.November 8, 2024 | marketbeat.comVaxcyte FY2024 EPS Forecast Boosted by Leerink PartnrsVaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of Vaxcyte in a research note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn ($3.6November 8, 2024 | marketbeat.comVaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical ChallengesNovember 7, 2024 | markets.businessinsider.comVaxcyte’s Strong Market Position and Financial Health Justify Buy Rating with $153 TargetNovember 7, 2024 | markets.businessinsider.comVaxcyte (NASDAQ:PCVX) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research note on Wednesday.November 6, 2024 | marketbeat.comVaxcyte Reports Progress and Strengthens Financial PositionNovember 6, 2024 | markets.businessinsider.comDecoding Vaxcyte Inc (PCVX): A Strategic SWOT InsightNovember 6, 2024 | finance.yahoo.comVaxcyte’s Strategic R&D Progress and Analyst ‘Buy’ Rating Reaffirmed with $140 TargetNovember 6, 2024 | markets.businessinsider.comVaxcyte (NASDAQ:PCVX) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday.November 6, 2024 | marketbeat.comVaxcyte Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 5, 2024 | globenewswire.comVaxcyte, Inc. (NASDAQ:PCVX) COO Sells $854,400.00 in StockNovember 5, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 8,000 SharesVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the sale, the chief operating officer now directly owns 205,695 shares of the company's stock, valued at approximately $21,968,226. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.November 4, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Harbor Capital Advisors Inc.Harbor Capital Advisors Inc. lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 60.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,664 shares of the company's stock after purchasingNovember 3, 2024 | marketbeat.comShould You Consider Investing in Vaxcyte (PCVX)?November 2, 2024 | msn.comRaymond James & Associates Buys 11,798 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Raymond James & Associates increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 81,235 shares of the company's stock after buying an additional 1October 30, 2024 | marketbeat.comVaxcyte (NASDAQ:PCVX) Trading Down 5.9% - Time to Sell?Vaxcyte (NASDAQ:PCVX) Shares Down 5.9% - Should You Sell?October 29, 2024 | marketbeat.comChina Universal Asset Management Co. Ltd. Grows Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)China Universal Asset Management Co. Ltd. raised its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 68.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,466 shares of the company's stock after buying aOctober 29, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) is Novo Holdings A S's 8th Largest PositionNovo Holdings A S decreased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 21.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 750,000 shares of the company's stock after selling 200,000 shares during the period. VaxcyteOctober 27, 2024 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Vaxcyte (PCVX)October 26, 2024 | markets.businessinsider.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Creative PlanningCreative Planning increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 37.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,525 shares of the company's stock after purchasinOctober 25, 2024 | marketbeat.comMoody Aldrich Partners LLC Trims Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)Moody Aldrich Partners LLC trimmed its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 46.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,169 shares of the company's stock after selling 46,117 sharesOctober 24, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $4,846,380.00 in StockOctober 23, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Buy" by BrokeragesShares of Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) have been given an average rating of "Buy" by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price target amonOctober 23, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by SG Americas Securities LLCSG Americas Securities LLC increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 306.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,530 shares of the company's stock after buying an additionOctober 11, 2024 | marketbeat.comTD Cowen Reaffirms Their Buy Rating on Vaxcyte (PCVX)October 10, 2024 | markets.businessinsider.comVaxcyte (NASDAQ:PCVX) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comMikhail Eydelman Sells 5,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockOctober 9, 2024 | insidertrades.com Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. PCVX Media Mentions By Week PCVX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCVX News Sentiment▼0.900.45▲Average Medical News Sentiment PCVX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCVX Articles This Week▼125▲PCVX Articles Average Week Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Scholar Rock News Today Sangamo Therapeutics News Today Editas Medicine News Today Adverum Biotechnologies News Today Atara Biotherapeutics News Today Takeda Pharmaceutical News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCVX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
